CI Bio-Revolution Index ETF

TSX TICKER : CDNA
 

Fund overview

The ETF seeks to replicate, to the extent reasonably possible, the performance of a global biotechnology and genomics industry index, net of expenses. Currently, the ETF seeks to replicate the performance of the Solactive Global Genomics Immunology and Medical Revolution CAD Hedged Index (the “Index”). The Index intends to track the performance of companies that have business operations in the global biotechnology and genomics industry using the ARTIS® classification system. The Index hedges foreign currency exposure back to Canadian dollars.

Fund details

description of elementelement value
Inception date February 2022
Total net assets ($CAD)
As at 2024-06-19
$5.6 million
NAVPS
As at 2024-06-19
$16.2841
Market price
As at 2024-06-19
$16.3200
MER (%)
As at 2023-12-31
0.44
Management fee (%) 0.40
Units outstanding
As at 2024-06-19
350,000
Asset class Sector Equity
Currency CAD
CUSIP 12545U100
Distribution frequency Quarterly
Last distribution $0.0189

Risk rating1

  • Low
  • Low to medium
  • Medium
  • Medium to high
  • High

Investor suitability

For those who:
  • want exposure to companies that are involved in the global biotechnology and genomics industry
  • are investing for the medium and/or long term
  • can tolerate medium to high risk

Performance2 As at 2024-05-31

Growth of $10,000 (Since inception date)

growth of 10k graph

Calendar year performance

annual performance graph

average annual compound returns

YTD 1 Mo 3 Mo 6 Mo 1 Y 3 Y 5 Y 10 Y Inception*
-7.79% 4.18% -8.76% 0.94% -10.35% - - - -8.19%
*Since inception date

Distribution history3

Payable date Total
2024-03-21 0.0189
2023-12-20 0.0350
2023-06-23 0.0348
2023-03-24 0.1870

Management team

First we'll display the Team Company and then the Team members
Lijon Geeverghese

CI Bio-Revolution Index ETF

TSX TICKER : CDNA
 
Portfolio allocations4 As at 2024-05-31
Asset allocation (%)
  • US Equity 74.19
  • International Equity 25.82
  • Cash and Equivalents 0.01
  • Other -0.02
Sector allocation (%)
  • Healthcare 99.99
  • Cash and Cash Equivalent 0.01
  • Other -0.02
Geographic allocation(%)
  • United States 73.92
  • Switzerland 9.01
  • Cayman Islands 3.03
  • Germany 2.73
  • United Kingdom 2.45
  • Netherlands 2.29
  • Denmark 1.99
  • France 1.68
  • Korea, Republic Of 1.59
  • Other 1.31
Top holdings
Sector (%)
1. Moderna Inc Drugs 4.56%
2. Twist Bioscience Corp Drugs 3.90%
3. PTC Therapeutics Inc Drugs 3.43%
4. Vertex Pharmaceuticals Inc Drugs 3.40%
5. Thermo Fisher Scientific Inc Healthcare Equipment 3.16%
6. Natera Inc Healthcare Equipment 3.13%
7. Lonza Group AG Drugs 3.12%
8. Sarepta Therapeutics Inc Drugs 3.01%
9. BioNTech SE - ADR Drugs 2.73%
10. Illumina Inc Healthcare Equipment 2.72%
11. AbbVie Inc Drugs 2.72%
12. Bio-Techne Corp Drugs 2.68%
13. Biogen Inc Drugs 2.62%
14. CRISPR Therapeutics AG Drugs 2.56%
15. Agilent Technologies Inc Healthcare Equipment 2.54%
Over 35,000 financial advisors have chosen CI Global Asset Management as a partner. We believe that Canadians have the best opportunity for investments success by using the services of a professional financial advisor. Learn more at ci.com.